Pioneering female doctor honoured in home town
The first female professor of medicine in Britain and Ireland, from County Antrim, has been recognised with an Ulster History Circle blue plaque.
The pioneering Dame Louise McIlroy was the first woman to graduate in medicine from Glasgow University in 1898.
After being told "battlefields are no place for a woman", Dame Louise defied officials and joined the newly formed Scottish Women's Hospitals for Foreign Service in 1914, with her first posting to France.
Anne Louise McIlroy was born at Lavin House on 11 November 1874 in the townland of Knockahollet, Loughguile, and her father James was the local GP.
She was one of four girls, and one of her sisters Jane also studied medicine and Glasgow and became an eye doctor.
The family relocated from Loughguile to Ballycastle where her father became the district's medical officer.
At the start of the World War One, Dame Louise served as a chief medical officer at a camp hospital in France. She was later sent to Serbia and then Salonika in Greece.
Dame Louise was faced with overcrowding, extreme weather, remoteness and disease as she cared for hundreds of patients in the tented hospitals.
After the war, she served as an assistant surgeon in Constantinople, now Istanbul, with the British Army Medical Corps.
In 1920 she was awarded the OBE for her war service. She was also awarded the Croix de Guerre by the French government.
In 1921, Dame Louise was appointed professor of Obstetrics and Gynaecology at the London School of Medicine for Women, now the Royal Free Hospital Medical School. Her salary, £2,000, was the highest paid to a woman for university work.
In 1929, her work was recognised and she was made a Dame for midwifery services.
Two years later Queen's University Belfast awarded her an honorary degree.
After retiring in 1934, Dame Louise came back to work at the start of World War Two to organise maternity services in Buckinghamshire.
After the war she returned to her retirement, living with her sister Jane in Ayrshire.
Dame Louise McIlroy died in 1968 and was buried in her family's grave at Ballycastle Presbyterian Church, where the plaque has been unveiled.
Chris Spurr, chairman of the Ulster History Circle, said Dame Louise McIlroy was a pioneering doctor from County Antrim who devoted her career to advancing the areas of obstetrics, gynaecology and child welfare.
Radar and microwave pioneer commemorated with blue plaque
Plaque for 'forgotten woman' of science
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Handwritten notes reveal Churchill's penicillin concern ahead of D-Day
Winston Churchill's push to obtain penicillin in time to treat casualties expected from D-Day has come to light in documents seen by BBC News. Official papers unearthed by the National Archives reveal the prime minister's frustration and concern over slow progress securing supplies of what was then seen to be a brand new "wonder drug". The BBC was shown the papers ahead of the anniversary of the Normandy landings on 6 June 1944. Even months after D-Day, the wartime prime minister called efforts "very disappointing" and bemoaned the fact the US was "so far ahead" despite the drug being a "British discovery". Penicillin was discovered in London by Professor Alexander Fleming in 1928. Despite attempts to produce a usable medicine from the bacteria-killing mould, this had not been achieved by the start of World War Two. But an Oxford team of scientists, led by Howard Florey, carried out the first successful trials. With large-scale production difficult in the UK, they took their research to the United States, where drug companies expanded output. Before the development of penicillin, blood poisoning could follow even minor wounds with no cure available. So with the anticipation of the huge military effort ahead, supplies of the drug were seen as essential. Early in 1944, the prime minister was complaining to his ministers about Britain's inability to produce it at scale. He scrawled in red ink on a Ministry of Supply report that said the Americans were producing greater quantities: "I am sorry we can't produce more". Later in the year, in response to explanations from officials, he said: "Your report on penicillin showing that we are only to get about one-tenth of the expected output this year, is very disappointing." On another report, he instructs: "Let me have proposals for a more abundant supply from Great Britain". Less than a fortnight before D-Day, health officials could report that sufficient supplies had been obtained, most from the US, but only for battle casualties. Dr Jessamy Carlson, modern records specialist at The National Archives, said: "The files give a glimpse into the extraordinary levels of preparation undertaken in advance of the D-Day landings. "Only six weeks before, penicillin is just reaching our shores in quantities which will allow it to play a major role in improving the outcomes for service personnel wounded in action." But what's now seen as the first true antibiotic would not be fully available to the general public till 1946. A telegram in the same files shows a doctor from Cornwall, who was treating a 10-year-old child in 1944, pleading with the authorities for the medicine: "No hope without penicillin". The plea was rejected, with supplies said to be only available for military use. With antibiotics now part of everyday life (and arguably too widely used), the documents seen by the BBC shed new light on the urgent efforts by Churchill and others to secure enough of one such drug for the first time to save lives during the struggle to liberate northern Europe. Major feared Churchill archive would be broken up How a tiny village became a penicillin powerhouse Pharmacists warn drug shortage affecting cancer patients
Yahoo
01-06-2025
- Yahoo
Former nurse, 100, 'inundated' with birthday cards
A former midwife has received hundreds of cards from around the world in celebration of her 100th birthday. Bertha Preston spent time working in New Zealand, Australia and Kenya, before settling down in a nursing career at Royal United Hospital (RUH) in Bath, Somerset. With no surviving family or close friends nearby, staff at the Bloomfield Care Centre in Paulton issued a "heartfelt request" to the public to send in their warm wishes. Key worker Jane Rogers described Ms Preston as a "very strong lady", who "chose her career over marriage" and showed an unwavering dedication to her profession. Ms Preston said "her spirit remains strong and her presence continues to inspire those around her". "She's been a huge part of my life," said Ms Rogers, who has cared for Ms Preston since 2009. "All of the residents here are very special to everyone who works here, but she's a darling lady. "Because of her vulnerability and the fact she has no known family, we've all become her family, and that's how we like it." Ms Preston's "quiet strength and compassion" was born out of becoming an orphan at the age of eight, after losing her mother to tuberculosis. Her nursing journey took her around the world, most notably to Africa, where she treated patients for trachoma and helped deliver hundreds of babies. One woman wrote to Ms Preston from Kenya to ask if she had worked at the hospital during her birth in the early 1960s. "I was delighted to read of your enthusiasm for the country, and of your hard work and devotion over many years as a nurse," Sarah wrote. "You are clearly a credit to your profession." Activities assistant Christina Coles said the home had been "inundated" with letters since posting the appeal online, including a card from King Charles III and Queen Camilla. "The amount that's come through the post has been amazing," she said. "We've had such a good response, it's really been overwhelming. "It's lovely that people have made so much effort in the community to come forward for a lady who has worked so hard. "100 years is an amazing achievement for anyone. Bertha has got an incredible story and it's nice to share that with people," she added. Follow BBC Somerset on Facebook and X. Send your story ideas to us on email or via WhatsApp on 0800 313 4630. D-Day veteran's 'unforgettable' 100th birthday World War Two decoder celebrates 100th birthday Vera celebrates 100th birthday with 450 cards Bloomfield Care Centre
Yahoo
23-05-2025
- Yahoo
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity Opinion follows FDA approval and MHRA conditional marketing authorisation European Commission (EC) decision on conditional marketing authorization application (MAA) expected within approximately two months LONDON, May 23, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended European Commission (EC) approval of obecabtagene autoleucel (obe-cel) for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). 'This positive CHMP opinion is a welcome advancement for physicians and patients in Europe, faced with treating r/r adult B-ALL patients with a poor prognosis,' said Dr. Claire Roddie, MD, PhD, FRCPath, Lead Investigator of the FELIX study and Associate Professor of Haematology at the University College London (UCL) Cancer Institute. 'Obe-cel's combination of favorable tolerability and potential long-term outcomes could offer an important new treatment option for patients in the EU.' The CHMP recommendation was based on the results of the FELIX study, an open-label, multi centre, single arm study in adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia. The results were published in the New England Journal of Medicine in November 20241. In the pivotal cohort of patients, (cohort IIA (n=94)), the Complete Response/Complete Response with Incomplete Haematological Recovery (CR/CRi) for patients who received at least one infusion of obecabtagene autoleucel was 76.6%. Median response duration for all infused patients was 21.2 months. Median event-free survival (EFS) was 11.9 months and the estimated 6- and 12-month event-free survival rates were 65.4% and 49.5%, respectively. The most common non-laboratory Grade 3 or higher adverse reactions were infections-pathogen unspecified (32%), febrile neutropenia (24%) and bacterial infectious disorders (11%). Cytokine release syndrome developed in 87 of the 127 patients (68.5%), with events of grade 3 or higher in three patients (2.4%). Immune effector cell-associated neurotoxicity syndrome developed in 29 of the 127 patients (22.8%), with grade 3 or higher occurring in nine patients (7%). 'This positive opinion from the CHMP highlights the significant unmet need and importance of effective treatment options for adult r/r B-ALL,' said Dr. Christian Itin, Chief Executive Officer of Autolus. 'With FDA approval received in November 2024 and an MHRA conditional marketing authorization received in April 2025, we are on our way to bringing this therapy to patients in need globally.' Obe-cel is an autologous CD19 CAR T cell therapy with a proprietary CD19 CAR, invented by a team led by Dr. Martin Pule, at University College London, along with collaborators at Great Ormond Street Hospital and University College London Hospital. The CAR is designed to have a fast 'off-rate' which mimics physiological T-cell receptor interactions2. ALL is an aggressive type of blood cancer that can also involve the lymph nodes, spleen, liver, central nervous system and other organs. In Europe, there are approximately 6,0002 new cases of ALL diagnosed every year. In frontline treatment for adult B-ALL, up to 50% of patients will ultimately relapse3. Survival rates remain very poor in adult patients with r/r ALL, with median overall survival of eight months with conventional treatments4, and the standard-of-care treatment can trigger severe toxicities5. The positive CHMP opinion is a scientific recommendation for marketing authorization, serving as a basis for the EC's final decision on Autolus' MAA for obe-cel for adult r/r B-ALL patients. The EC is expected to make a decision following CHMP recommendation, and the decision will apply to all 27 European Union Member States, Iceland, Norway and Liechtenstein. Obe-cel is currently approved by the U.S. Food and Drug Administration (FDA) (Nov 8, 2024), and authorized by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) (April 25, 2025). References Roddie C, et al "Obecabtagene autoleucel in B-cell acute lymphoblastic leukemia" N Engl J Med 2024; DOI: 10.1056/NEJMoa2406526 Cancer Research UK - Aureli A, Marziani B, Venditti A, Sconocchia T, Sconocchia G. Acute lymphoblastic leukemia immunotherapy treatment: now, next, and beyond. Cancers (Basel). 2023;15:3346. Dhakal P, Kaur J, Gundabolu K, Bhatt VR. Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents? Leuk Lymphoma. 2020;61:7-17. About Autolus Therapeutics plcAutolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved and MHRA licensed product, obe-cel, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit obe-cel FELIX clinical trialAutolus' Phase 1b/2 clinical trial of obe-cel enrolled adult patients with r/r B-precursor ALL. The trial had a Phase 1b component prior to proceeding to the single arm, Phase 2 clinical trial. The primary endpoint in the pivotal cohort was overall response rate, and the secondary endpoints included duration of response, MRD negative complete remission rate and safety. The trial enrolled over 100 patients across 30 of the leading academic and non-academic centers in the United States, United Kingdom and Europe. [NCT04404660]. Forward Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These risks and uncertainties include, but are not limited to the impact of worsening macroeconomic conditions on Autolus' business, financial position, strategy and anticipated milestones, including Autolus' ability to conduct ongoing and planned clinical trials; Autolus' ability to obtain a clinical supply of current or future product candidates or commercial supply of obe-cel or any future approved products; Autolus' ability to obtain and maintain regulatory approval of its product candidates, including obe-cel and potential expansions into additional indications; Autolus' ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell obe-cel and any future approved products; Autolus' ability to obtain marketing approval for obe-cel in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Autolus' ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates, including obe-cel and potential expansions into additional indications; Autolus' ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell obe-cel and any future approved products; Autolus' ability to obtain marketing approval for obe-cel in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Autolus' ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; and possible safety and efficacy concerns. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus' actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 10-K filed with the Securities and Exchange Commission, or the SEC, on March 20, 2025 as well as discussions of potential risks, uncertainties, and other important factors in Autolus' subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing Autolus' views as of any date subsequent to the date of this press release. Contact: Amanda Cray +1 617-967-0207 Olivia Manser +44 (0) 7780 471 568 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
